3 ms·
Given the multiple issues Martin has faced over the years, I think it's fair to say that 'impartiality' is the least of his motivations. "If an analyst looks a
by FireBeyond 11y ago
Given the multiple issues Martin has faced over the years, I think it's fair to say that 'impartiality' is the least of his motivations.
"If an analyst looks at the data and sees issues" - what are they? A stockbroker, or pharmaceutical scientist? How many are both?
It would only make financial sense to push for the drug not to be approved -if- you had a position that made a gain from that, but let's not pretend like Martin was doing so out of any source of ethics.
- cowsandmilk 11y agoI don't care about Shkreli, I care about whether the practice is ethical. There are plenty of pharma analysts who have used the same techniques who have medical degrees, have worked on clinical trial design at pharma companies, etc. They often aren't the names you see when pharma complains about people shorting their stocks because pharma only wants to point at the head of the hedge fund who has no life sciences expertise. They don't want the public to know about the dozen experts the hedge fund manager is paying to analyze the filings in order to challenge the filings and decide whether to short the stock. No one complains if your analysis shows the molecule is great and you go long, it only becomes evil if your analysis shows the molecule is crap.
- FireBeyond 11y agoAnd if pharma analysts who have medical degrees want to analyze filings from these companies, great. But the specific example is talking about Martin Shkreli doing this - a man whose formal education is a Bachelor of Business from CUNY. And ethics have roots in motivations. Shkreli couldn't give two hoots whether the drugs had efficacy or not. He wanted them to fail approval only because of his position in the companies.